CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer

© 2018 American Society of Clinical Oncology. Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Manuel Cobo, Eun Kyung Cho, Alessandro Bertolini, Sabine Bohnet, Caicun Zhou, Ki Hyeong Lee, Naoyuki Nogami, Isamu Okamoto, Natasha Leighl, Rachel Hodge, Astrid McKeown, Andrew P. Brown, Yuri Rukazenkov, Suresh S. Ramalingam, Johan Vansteenkiste
Other Authors: Yonsei Cancer Center
Format: Conference or Workshop Item
Published: 2019
Subjects:
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/44997
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University